Abdominal Tuberculosis — GI TB vs Crohn Differential NEET PG 2027

Abdominal Tuberculosis — GI TB vs Crohn Differential NEET PG 2027 | NEETPGAI

Quick Answer

Abdominal tuberculosis is a 2 to 3 question topic per NEET PG paper across medicine, surgery, and community medicine — highly India-relevant. Lock these:

Forms — intestinal (ileocecal commonest), peritoneal (wet ascites, dry adhesive, fibrous encasing), lymph nodal (mesenteric matted with caseation), solid-organ (hepatic, splenic, adrenal).
Intestinal TB — transverse ulcers, short concentric strictures, hyperplastic ileocecal mass.
Peritoneal TB wet type — high-protein ascites, SAAG less than 1.1, lymphocyte-predominant, ADA over 40 U/L.
Doughy abdomen + rope-like mesentery — dry adhesive peritoneal TB.
Investigations — USG matted bowel + clubbed mesentery, CECT, ascitic ADA, Xpert MTB/RIF, MGIT culture, laparoscopy + biopsy (gold standard).
Colonoscopy TB — transverse ulcers, short strictures, heaped edges.
Colonoscopy Crohn — longitudinal ulcers, skip lesions, cobblestoning.
Biopsy — TB shows large caseating granulomas; Crohn small non-caseating.
ATT — 2 months HRZE + 4 months HR (RIPE); 6 months standard; extend to 9-12 in abdominal TB if slow response.
Monitor — LFTs (INH, RIF, PZA hepatotoxic), colour vision (ethambutol optic neuritis), uric acid (PZA), adherence via DOT/99DOTS.
Surgery indications — obstruction not resolving, stricture, perforation, hemorrhage, fistula, unresolved mass (exclude malignancy).
NTEP — Ni-kshay portal mandatory notification; Ni-kshay Poshan Yojana Rs 500/month DBT; free ATT.

Abdominal tuberculosis is a defining Indian medicine and surgery diagnosis — you will see this in every internal medicine and surgery long case, and NEET PG tests it repeatedly. This deep dive walks through anatomic forms → clinical presentation → investigations including ascitic fluid analysis → the intestinal-TB-vs-Crohn discrimination → ATT protocol → surgical indications → India NTEP context.

Epidemiology and importance

India accounts for over one-quarter of the global TB burden (over 2.6 million cases per year)
Abdominal TB accounts for about 15 percent of extrapulmonary TB in India
Rising in HIV-endemic populations and in urban migrants with crowded living
Mimics Crohn disease, malignancy, and lymphoma — mis-diagnosis is common and dangerous

Anatomic forms

1. Intestinal TB

Ileocecal region most common — physiological stasis, high lymphoid density, abundant M cells
Also involves jejunum, ileum, and less commonly colon
Types:
- Hyperplastic (mass forming) — thickened ileocecal wall forming a palpable RLQ mass — mimics Crohn or malignancy
- Ulcerative — transverse ulcers perpendicular to bowel long axis (in contrast to longitudinal in Crohn)
- Stricturing — short concentric strictures causing subacute intestinal obstruction (a very common Indian presentation)
- Fistulating — enterocutaneous, enteroenteric fistulas

2. Peritoneal TB

Wet (ascites-forming) type — commonest peritoneal presentation; high-protein exudative ascites with lymphocyte predominance
Dry (adhesive) type — rope-like mesenteric thickening, matted bowel loops, subacute obstruction; doughy abdomen on palpation
Fibrous encasing type — rare; encapsulating peritonitis with peel-like fibrosis; may need surgical debridement

3. Lymph nodal TB

Mesenteric and retroperitoneal nodes — matted enlarged with caseous necrosis and eventual calcification on imaging
May present as abdominal mass, fever of unknown origin, or incidental radiologic finding

4. Solid-organ TB

Hepatic TB — miliary pattern, macronodular tuberculomas, TB cholangitis
Splenic TB — miliary; splenomegaly with hypoechoic lesions
Adrenal TB — bilateral adrenal enlargement causing Addison disease (a classic Indian medicine long-case)
Pancreatic TB — rare; mimics pancreatic malignancy

Clinical presentation

Chronic (weeks to months)

Low-grade fever, night sweats, weight loss, anorexia
Crampy abdominal pain
Doughy abdomen on palpation (dry adhesive peritoneal TB)
Palpable ileocecal mass (hyperplastic intestinal TB) in RLQ — cannonball
Ascites (wet peritoneal TB)
Hepatomegaly, splenomegaly (visceral TB)

Acute (surgical presentations)

Intestinal obstruction (stricturing intestinal TB)
Intestinal perforation with peritonitis
Massive GI bleeding
Enterocutaneous or enteroenteric fistula

Systemic features

Coexistent pulmonary TB in about 15 percent — always do chest X-ray
Extrapulmonary sites elsewhere — nodes, spine, adrenal
HIV coinfection screening mandatory

Investigations

Laboratory

CBC — normocytic anaemia, mild leukocytosis, lymphopenia in advanced
ESR, CRP — usually raised
LFTs — baseline before ATT
HIV serology — mandatory
Mantoux (TST) — supportive; false negatives in advanced disease, false positives from BCG
Interferon-gamma release assay (IGRA — QuantiFERON, T-SPOT.TB) — supportive; endemic false positives limit specificity in India

Chest X-ray

Pulmonary TB in about 15 percent of abdominal TB
Miliary pattern raises suspicion of disseminated TB

Ascitic fluid analysis (for wet peritoneal TB)

Parameter	Peritoneal TB	Malignant	SBP	Portal hypertensive (cirrhosis)
Appearance	Straw to turbid	Bloody, chylous	Cloudy	Clear
Cell count	150-4000/microlitre	Variable	Over 250 PMN	Under 250
Predominant cell	Lymphocyte	Malignant cells	Neutrophil	Lymphocyte or mesothelial
Protein	Over 3 g/dL (high)	Over 3 g/dL	Variable	Under 2.5 g/dL
SAAG	Less than 1.1	Less than 1.1	Less than 1.1	Greater than 1.1
Glucose	Low (less than serum)	Low	Low	Normal
LDH	Raised	Raised	Raised	Normal
ADA	Greater than 40 U/L	Under 40	Under 40	Under 40
AFB smear	Low yield (paucibacillary)	—	—	—
Xpert MTB/RIF	Fast, positive	—	—	—
Culture (MGIT)	Gold standard (4-6 weeks)	—	—	—
Cytology	—	Malignant cells positive	—	—

Imaging

Abdominal USG — ascites (may be loculated), matted mesenteric thickening (clubbed mesentery), thickened peritoneum, mesenteric lymphadenopathy, ileocecal wall thickening
CECT abdomen — high-resolution; wall thickening (especially ileocecal), strictures, matted bowel loops, mesenteric lymphadenopathy with caseous necrosis (hypodense centres), splenic hypodense lesions, adrenal enlargement
MRI enterography — for suspected small bowel involvement; better soft-tissue detail; distinguishes from Crohn
Barium studies — largely replaced by CT and endoscopy but still used for jejunoileal strictures (small bowel enteroclysis)

Endoscopy

Colonoscopy with ileoscopy — assesses ileocecal disease; transverse ulcers, short concentric strictures, hyperemic mucosa, deformed ileocecal valve; biopsy for AFB stain, Xpert MTB/RIF, MGIT culture, histology (large caseating granulomas)
Upper GI endoscopy — if upper GI symptoms; jejunal strictures

Definitive tissue diagnosis

CT-guided or laparoscopy-guided biopsy — histology (caseating granulomas), AFB stain, Xpert MTB/RIF, MGIT culture
Laparoscopy — direct visualisation shows classical whitish tubercles studded on parietal peritoneum, thickened matted mesentery, adhesions; laparoscopic biopsy yield over 95 percent; gold standard when non-invasive work-up inconclusive

Distinguishing intestinal TB from Crohn disease

Feature	Intestinal TB	Crohn disease
Prevalence in India	High (endemic)	Rising with westernisation but far less common
Symptom duration	Shorter (often under 12 months)	Longer (often over 12 months)
Constitutional symptoms	Prominent fever, night sweats, weight loss	Less prominent; more diarrhoea
Extraintestinal manifestations	Uncommon	Common (arthritis, uveitis, pyoderma, erythema nodosum, sclerosing cholangitis)
Perianal disease	Uncommon	Common (fistulas, fissures, tags)
Ulcer pattern (colonoscopy)	Transverse ulcers, heaped edges	Longitudinal ulcers, cobblestoning
Distribution	Ileocecal predominant, less skip	Skip lesions common
Strictures	Short concentric	Long, tapered
Biopsy granuloma	Large confluent caseating	Small non-caseating (or absent)
Transmural inflammation	Less prominent	Prominent
ASCA	Negative	Positive (about 60 percent)
pANCA	Positive in some	Positive in ulcerative colitis
Xpert MTB/RIF on biopsy	Positive	Negative
AFB stain / culture	Positive	Negative
IGRA	Positive (endemic false positives)	May be positive from prior exposure
Response to ATT	Improvement in 4-8 weeks	No improvement
Response to steroids and biologics	Deterioration risk (TB dissemination)	Improvement

The therapeutic ATT trial

When diagnosis remains uncertain after standard work-up, a therapeutic trial of ATT for 8-12 weeks is offered in Indian practice:

Clinical + endoscopic + radiologic response supports TB → complete full ATT course
No response supports Crohn → stop ATT, initiate biologic therapy after appropriate work-up
Never start steroids for suspected Crohn without excluding TB — steroids can catastrophically disseminate TB

Standard ATT regimen (India NTEP)

Intensive phase (2 months) — HRZE daily

H — Isoniazid
R — Rifampicin
Z — Pyrazinamide
E — Ethambutol

Continuation phase (4 months) — HR daily

H — Isoniazid
R — Rifampicin

Duration by site

Site	Duration
Uncomplicated pulmonary + most extrapulmonary	6 months
Abdominal TB with slow response	6-9 months (extend continuation phase)
Severe abdominal, CNS, skeletal, disseminated	9-12 months
MDR-TB	Longer, individualised (bedaquiline-based)

Weight-band dosing and fixed-dose combinations (FDC)

Provided free through NTEP as weight-band FDCs

First-line drug toxicities to monitor

Drug	Major toxicities	Monitoring
Isoniazid (H)	Hepatotoxicity, peripheral neuropathy (add pyridoxine 10-25 mg/day), lupus-like syndrome	LFTs, neuro exam
Rifampicin (R)	Hepatotoxicity, orange discolouration of secretions (warn patient), CYP450 induction (reduces OCP + ART efficacy), flu-like syndrome, thrombocytopenia	LFTs, CBC
Pyrazinamide (Z)	Hepatotoxicity, hyperuricaemia (gout flare), arthralgia	LFTs, uric acid
Ethambutol (E)	Optic neuritis (colour vision, especially red-green — reversible if caught early), peripheral neuropathy	Snellen chart, Ishihara plates monthly

Hepatotoxicity management

Discontinue all hepatotoxic drugs if ALT over 3-5× ULN with symptoms, or over 5× ULN without symptoms
Wait for LFTs to normalise
Reintroduce sequentially — R first (least hepatotoxic of RIZ), then I, then Z if tolerated; if PZA-related, may complete regimen without PZA (extended duration)

Adherence support

DOT (Directly Observed Therapy) — historically in-person; now increasingly virtual
99DOTS — missed-call verification of medication ingestion (patient makes a toll-free call after ingestion)
Video-observed therapy (VOT) — video verification
Ni-kshay portal — digital tracking of every notified case; contact tracing, drug-susceptibility testing, adherence
Non-adherence is the biggest driver of relapse and MDR generation

Surgical indications in abdominal TB

Surgery is reserved for complications and is complementary to medical therapy (never a substitute).

Indication	Procedure
Acute intestinal obstruction not resolving in 48-72 hours	Emergency laparotomy — resection, stricturoplasty, or diversion
Short TB strictures causing recurrent subacute obstruction (no response to 4-6 week ATT trial)	Stricturoplasty (short single) or limited resection with anastomosis (multiple close-set or long)
Intestinal perforation with peritonitis	Emergency laparotomy — resection and anastomosis or diversion
Massive GI bleeding not endoscopically controlled	Emergency laparotomy
Enterocutaneous or enteroenteric fistula not resolving on ATT	Elective resection after nutritional optimisation
Ileocecal mass not distinguishable from malignancy	Right hemicolectomy for diagnosis + treatment
Large symptomatic cold abscess with mass effect	Drainage
Diagnostic uncertainty after non-invasive work-up	Laparoscopic peritoneal biopsy

India-specific programmatic context

NTEP (National TB Elimination Programme)

Replaces RNTCP; renamed 2020
India's goal — TB elimination by 2025 (revised from SDG 2030)
Free diagnosis, treatment, drug-susceptibility testing
Active case finding drives

Ni-kshay portal

Mandatory notification of every TB case (public + private practitioners) under Gazette Notification 2018
Digital tracking — drug-susceptibility testing, contact tracing, adherence, outcome
Non-notification is a punishable offence

Ni-kshay Poshan Yojana

Direct benefit transfer of Rs 500 per month for the duration of TB treatment as nutritional support
Reduces treatment abandonment and improves outcomes

Diagnostics

Xpert MTB/RIF Ultra — rapid PCR with rifampicin resistance detection (hours)
Line probe assays — for MDR/XDR detection
MGIT culture — gold standard for definitive diagnosis (4-6 weeks)
Free at NTEP-linked laboratories

MDR/XDR-TB management (PMDT)

Programmatic Management of Drug-Resistant TB
BPaL regimen — Bedaquiline + Pretomanid + Linezolid (6 months) for pre-XDR/XDR
BPaLM regimen — BPaL + Moxifloxacin (6 months) for MDR
Shorter, all-oral, better tolerated than historic 18-24 month MDR regimens
Approved by CDSCO and being rolled out through NTEP

TB Preventive Therapy (TPT)

Household contacts of TB patients (especially children under 6 years and HIV-positive)
Isoniazid 6 months, or 3HP (isoniazid + rifapentine weekly for 3 months), or 4R (rifampicin 4 months)
HIV-positive patients regardless of contact — INH preventive therapy

Related schemes

Ayushman Bharat PM-JAY — hospitalisation packages including TB surgery
State schemes — Arogyasri, Karunya, Amma
DBT for tribal / vulnerable populations — additional nutritional support in some states

NEET PG MCQ traps

Abdominal TB accounts for ~15 percent of extrapulmonary TB in India.
Ileocecal region — commonest intestinal TB site (physiological stasis + lymphoid tissue).
Transverse ulcers — intestinal TB (perpendicular to bowel long axis).
Longitudinal ulcers + cobblestoning — Crohn disease.
Peritoneal TB wet type — high-protein exudative ascites, lymphocyte-predominant.
SAAG less than 1.1 — TB peritonitis, malignancy; SAAG over 1.1 — portal hypertension (cirrhosis).
Ascitic ADA over 40 U/L — supports TB peritonitis (90 percent sensitivity/specificity in India).
Doughy abdomen — dry adhesive peritoneal TB.
Rope-like mesentery / clubbed mesentery — matted mesenteric thickening; USG classic.
Laparoscopy with biopsy — gold standard when non-invasive work-up inconclusive.
Xpert MTB/RIF Ultra — rapid PCR with rifampicin resistance; game-changer.
Adrenal TB — bilateral adrenal enlargement → Addison disease.
Hepatic TB — miliary, macronodular tuberculoma, TB cholangitis.
HRZE 2 months + HR 4 months — standard 6-month ATT.
Abdominal TB with slow response — extend to 9-12 months.
Isoniazid + pyridoxine — prevent peripheral neuropathy.
Rifampicin — orange secretions, CYP450 induction (reduces OCP, ART).
Pyrazinamide — hyperuricaemia + hepatotoxicity + arthralgia.
Ethambutol — optic neuritis (red-green colour vision loss); reversible if caught early.
INH + RIF + PZA all hepatotoxic — stop if ALT over 3-5x ULN with symptoms.
DOT / 99DOTS / VOT — adherence support in NTEP.
Ni-kshay notification — mandatory under Gazette Notification 2018.
Ni-kshay Poshan Yojana — Rs 500/month DBT nutritional support.
Never start steroids for suspected Crohn without excluding TB — TB dissemination risk.
ATT therapeutic trial 8-12 weeks — supports diagnosis if response.
Surgery indications — obstruction not resolving, stricture, perforation, hemorrhage, fistula, unresolved ileocecal mass.
Stricturoplasty — short single strictures; resection — multiple close-set or long.
BPaL / BPaLM — new MDR-TB oral regimens (6 months).
TPT for household contacts under 6 years + HIV-positive — INH 6 months or 3HP or 4R.

Recent updates and Indian context

BPaL / BPaLM regimens — 6-month all-oral MDR-TB treatment (bedaquiline, pretomanid, linezolid, moxifloxacin) approved by CDSCO and being rolled out through NTEP
Xpert MTB/RIF Ultra — replacing older Xpert cartridges; more sensitive for paucibacillary TB (including abdominal)
TB Preventive Therapy (TPT) expansion — increasing coverage of household contacts and HIV-positive patients
Active case finding drives — house-to-house campaigns in high-burden districts
AI-based CXR reading — Qure.ai qXR deployed at multiple NTEP centres for pulmonary TB screening
Ni-kshay 2.0 — enhanced digital platform for TB notification, contact tracing, adherence, outcome tracking
Private-provider engagement — Joint Effort for Elimination of TB (JEET) programme incentivises private sector notification
PMJAY — hospitalisation and surgery packages for complicated abdominal TB
Indigenous mycobacterial culture and drug-susceptibility infrastructure scaling — GeneXpert machines at district level

Frequently asked questions

What are the main forms of abdominal tuberculosis and how do they present?

Abdominal tuberculosis is highly India-relevant, accounting for about 15 percent of extrapulmonary TB in India, and takes 4 broad forms — (1) intestinal TB, (2) peritoneal TB, (3) lymph nodal TB, and (4) visceral or solid-organ TB. Intestinal TB most commonly involves the ileocecal region because of physiological stasis, high lymphoid tissue density, and abundant M cells; it can be hyperplastic (mass forming, mimicking Crohn disease or malignancy — the classic ileocecal mass palpable in RLQ), ulcerative (transverse ulcers oriented perpendicular to the long axis of the bowel — in contrast to the longitudinal ulcers of Crohn), stricturing (short concentric strictures causing subacute intestinal obstruction — a very common presentation in India), or fistulating. Peritoneal TB has three types — wet ascites-forming type (the most common presentation — high-protein exudative ascites with lymphocyte predominance; classical low SAAG less than 1.1), dry adhesive type (rope-like mesenteric thickening and matted bowel loops causing subacute obstruction and abdominal doughy feel on palpation), and fibrous encasing type (rare; encapsulating peritonitis with peel-like fibrosis). Lymph nodal TB involves mesenteric and retroperitoneal nodes — matted enlarged nodes with caseous necrosis and eventual calcification on imaging; may present as an abdominal mass or fever of unknown origin. Solid-organ TB includes hepatic TB (miliary pattern, macronodular tuberculomas, or TB cholangitis), splenic TB (typically miliary; splenomegaly with hypoechoic lesions), and adrenal TB (bilateral adrenal enlargement causing Addison disease — a classic Indian medicine long-case). Clinical presentation is chronic weeks-to-months of low-grade fever with night sweats, weight loss, anorexia, crampy abdominal pain, and a doughy abdomen on palpation; acute presentations include intestinal obstruction, perforation, or GI bleeding.

How do you distinguish intestinal TB from Crohn disease in the Indian setting?

Distinguishing intestinal TB from Crohn disease is one of the highest-yield discriminations in Indian gastroenterology because TB is far more common than Crohn in India, treatment is opposite (steroids and biologics for Crohn versus ATT for TB), and mis-treating one for the other causes serious harm — steroids can disseminate TB catastrophically. Both diseases love the ileocecal region and both present chronically. Discriminating features supporting TB — shorter symptom duration (often less than 12 months), constitutional symptoms more prominent (fever, night sweats, weight loss), pulmonary or extrapulmonary TB elsewhere (chest X-ray shows pulmonary TB in about 15 percent), ascites with high ADA over 40 U/L and lymphocyte predominance, colonoscopy showing transverse ulcers with heaped edges and short concentric strictures, biopsy with large confluent caseating granulomas and AFB staining or PCR positive, positive interferon-gamma release assay (though endemic false positives), and improvement on a therapeutic ATT trial. Discriminating features supporting Crohn — longer symptom duration (often over 12 months), extraintestinal manifestations (arthritis, uveitis, pyoderma gangrenosum, erythema nodosum, sclerosing cholangitis), perianal disease (fistulas, fissures, tags), colonoscopy showing skip lesions with longitudinal ulcers and cobblestoning, biopsy with small non-caseating granulomas or transmural inflammation without granulomas, positive ASCA (anti-Saccharomyces cerevisiae antibody) and negative pANCA (or vice versa), and no response to a trial of ATT. When diagnosis remains uncertain after standard work-up (CBC, ESR, chest X-ray, colonoscopy with biopsy, imaging, IGRA), a therapeutic trial of ATT for 8-12 weeks is offered in Indian practice — clinical and endoscopic response supports TB, non-response supports Crohn (and prompts biologic therapy). Xpert MTB/RIF Ultra on biopsy tissue is the newest game-changer — rapid PCR with rifampicin resistance detection in a few hours; increasingly available at NTEP-linked laboratories.

What is the workup for suspected peritoneal TB and how do you interpret ascitic fluid?

Peritoneal TB (ascites-forming wet type) is one of the classic causes of chronic exudative ascites in India and must be actively excluded in any patient with new ascites and constitutional symptoms. First-line investigation is diagnostic paracentesis with ascitic fluid analysis — appearance (straw-coloured to turbid), cell count and differential (typically 150-4000 WBC/microlitre with lymphocyte predominance greater than 50 percent — in contrast to spontaneous bacterial peritonitis which is neutrophilic and cell count higher; malignant ascites can have variable cell counts), protein (high — greater than 3 g/dL, exudative), SAAG (serum-ascites albumin gradient less than 1.1 g/dL supports peritoneal disease including TB and malignancy; SAAG greater than 1.1 supports portal hypertension), glucose (low compared with serum), LDH (raised), and adenosine deaminase (ADA) — over 40 U/L on ascitic fluid strongly supports TB peritonitis with sensitivity and specificity both around 90 percent in high-prevalence settings like India (lower in low-prevalence settings). AFB smear on ascitic fluid is low yield (paucibacillary); mycobacterial culture (MGIT) takes 4-6 weeks and has moderate yield; Xpert MTB/RIF on ascitic fluid is faster (hours) and detects rifampicin resistance. Imaging — abdominal ultrasound and CECT show ascites (may be loculated), matted mesenteric thickening (clubbed mesentery on USG), thickened peritoneum, matted bowel loops, mesenteric lymphadenopathy with caseous necrosis, and often coexistent intestinal or lymph nodal TB. Definitive diagnosis when non-invasive work-up is inconclusive is laparoscopy with peritoneal biopsy — direct visualisation shows classical whitish tubercles studded on parietal peritoneum, thickened matted mesentery, and adhesions; histology confirms caseating granulomas and PCR/culture confirms mycobacteria — laparoscopic yield is over 95 percent and it is the gold standard for definitive diagnosis when other tests are inconclusive.

What is the standard ATT regimen for abdominal TB and how is it monitored?

The standard ATT regimen for abdominal tuberculosis under India's National TB Elimination Programme (NTEP, formerly RNTCP) follows the WHO-recommended RIPE approach — 2 months of intensive phase with rifampicin, isoniazid, pyrazinamide, and ethambutol (HRZE) daily, followed by 4 months of continuation phase with rifampicin and isoniazid (HR) daily; total 6 months for uncomplicated pulmonary and most extrapulmonary TB. However, abdominal TB (and CNS, skeletal, and disseminated TB) is often treated for a longer 6-9 months if response is slow, or a full 9-12 months in severe cases, extended further to 18 months for MDR-TB or refractory disease. Weight-band dosing is used through the fixed-dose combination (FDC) tablets supplied through NTEP. Monitoring is essential and multi-faceted — clinical response (weight gain, symptom resolution, decreasing abdominal pain and ascites) is expected within 4-8 weeks; failure to improve at 8-12 weeks warrants reassessment for wrong diagnosis (Crohn, malignancy), MDR-TB, or non-adherence. Baseline and monthly LFTs monitor for hepatotoxicity (INH, RIF, PZA all hepatotoxic; discontinue if ALT rises over 3-5 times upper limit with symptoms, or over 5 times without symptoms; reintroduce sequentially once normalised — the R-I-Z order); baseline colour vision and Snellen chart monitor for ethambutol optic neuritis (rare at recommended dose but reversible only if caught early); baseline uric acid and joint symptoms for pyrazinamide arthralgia; audiometry not needed for first-line drugs but essential if aminoglycosides added for MDR. Adherence is supported through daily observed therapy (DOT) — historically in-person, now increasingly through the 99DOTS system (missed-call verification of medication ingestion), video-observed therapy (VOT), and the Ni-kshay portal digital tracking; adherence failure is the biggest driver of relapse and MDR generation. All TB cases must be notified via Ni-kshay (mandatory under Gazette Notification 2018) and the patient enrolled for Ni-kshay Poshan Yojana — Rs 500 per month DBT nutritional support for the duration of treatment.

When is surgery indicated in abdominal TB and how does India's NTEP support these patients?

Surgery in abdominal TB is reserved for complications that cannot be managed by ATT alone and is complementary to medical therapy — not a substitute. Absolute or urgent surgical indications include (1) acute intestinal obstruction that does not resolve with conservative measures (nasogastric decompression, IV fluids, antibiotics) within 48-72 hours; (2) short concentric TB strictures causing recurrent subacute obstruction not responding to a 4-6 week ATT trial — treated by stricturoplasty (for short single strictures) or limited resection with anastomosis (for multiple close-set strictures or long strictures); (3) intestinal perforation with peritonitis — emergency laparotomy with resection or repair; (4) massive GI bleeding not controlled endoscopically — emergency laparotomy; (5) enterocutaneous or enteroenteric fistula not resolving on ATT; (6) inability to exclude malignancy in an ileocecal or colonic mass — right hemicolectomy for diagnosis and treatment; and (7) drainage of large cold abscess causing mass effect. Laparoscopic peritoneal biopsy is diagnostic surgery — not therapeutic — and is offered when non-invasive work-up is inconclusive. Under India's NTEP framework — every diagnosed TB case (including abdominal TB) is notified via the Ni-kshay portal (mandatory under Gazette Notification 2018 — both public and private practitioners must notify); the patient is enrolled for the Ni-kshay Poshan Yojana, a direct benefit transfer (DBT) of Rs 500 per month for the duration of treatment as nutritional support; ATT is provided free through district TB centres and public health facilities; drug-susceptibility testing (Xpert MTB/RIF Ultra, line probe assays, MGIT culture) is provided free through NTEP-linked laboratories; MDR-TB and XDR-TB are managed under the Programmatic Management of Drug-Resistant TB (PMDT) with bedaquiline, pretomanid, linezolid, moxifloxacin (BPaL/BPaLM regimens increasingly rolled out); TB Preventive Therapy is provided for household contacts and HIV-positive patients; Ayushman Bharat PM-JAY covers hospitalisation and surgery packages; India's goal is TB elimination by 2025 (revised from SDG 2030), driving active case finding, drug-resistance screening, and social support scaling.

This content is for educational purposes for NEET PG exam preparation. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical information has been reviewed by qualified medical professionals.

Written by: NEETPGAI Editorial Team Reviewed by: Pending SME Review Last reviewed: July 2026